SD 1 swav-formsdfy2022.htm SD Document

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM SD
 
SPECIALIZED DISCLOSURE REPORT 
SHOCKWAVE MEDICAL, INC.
(Exact Name of Registrant as Specified in its Charter)
 
 
Delaware 001-38829 27-0494101
(State or other jurisdiction of
incorporation or organization)
 (Commission File Number) 
(IRS Employer
Identification No.)
 
5403 Betsy Ross Drive, Santa Clara, California 95054
(Address of Principal Executive Offices) (Zip Code)
Hajime Tada
General Counsel
(510) 279-4262
(Name and telephone number, including area code, of the person to contact in connection with this report.)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
 
xRule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period January 1, 2022 to December 31, 2022
 
 
 



image_0.jpg
Item 1.01.Conflict Minerals Disclosure and Report.
A copy of the Conflict Minerals Report of Shockwave Medical, Inc. (“Shockwave”) for the reporting period January 1, 2022 to December 31, 2022 is filed as Exhibit 1.01 to this specialized disclosure report on Form SD and is also available at Shockwave’s website at https://ir.shockwavemedical.com/financial-information/sec-filings.
 
Item 1.02.Exhibit.
Shockwave has filed, as an exhibit to this Form SD, a Conflict Minerals Report as required by Item 1.01 of this Form.
 
Item 3.01.Exhibits.
 



image_0.jpg
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
 
  SHOCKWAVE MEDICAL, INC.
Dated: May 26, 2023
 By: /s/ Daniel Puckett
 Name: Daniel Puckett
 Title: Chief Financial Officer